Nexalis Issues New Shares as It Accelerates Clinical Drug Programs

InhaleRx Limited ( (AU:NX1) ) has issued an announcement.

Nexalis Therapeutics has issued 780,000 ordinary shares on 23 February 2026 and confirmed the transaction was conducted without a prospectus under relevant Corporations Act provisions. The company states it is fully compliant with its periodic reporting and continuous disclosure obligations, and that there is no excluded information that would affect informed trading in its securities.

The share issue supports the company’s ongoing capital needs as it progresses multiple late-stage clinical programs in pain and mental health. With an existing funding facility of up to $52.3 million, Nexalis is positioning itself to accelerate development toward U.S. regulatory approvals, aiming to capitalise on significant commercial opportunities in areas of high unmet medical need.

The most recent analyst rating on (AU:NX1) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:NX1 Stock Forecast page.

More about InhaleRx Limited

Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company focused on rapid-onset therapies for unmet needs in pain management and mental health. It is advancing IRX-211 for breakthrough cancer pain, IRX-616a for panic disorder, and SRX-25 for treatment-resistant depression, targeting U.S. FDA approval via expedited regulatory pathways such as 505(b)(2).

Average Trading Volume: 272,864

Technical Sentiment Signal: Sell

Current Market Cap: A$7.32M

See more insights into NX1 stock on TipRanks’ Stock Analysis page.